ScholarLens Back to search
2001•Unpublished venueRequires access

Clinical efficacy of simvastatin in treating hyperlipidemia in the type 2 diabetes

WU Ji-chua

Open publisher page 0 citations

Abstract

Objective:To evaluate the curative efficacy and safety of treating the type 2 diabetic hy-perlipidemia with simvastatin 20 mg/tablet. Methods: Sixty patients of type 2 diabetes hyperlipidemiawere divided randomly into 2 groups. Thirty patients separately were given simvastatin orally 5 mg/tablet(LDL) or 20 mg/tablet in evening for 4 wk. Results: Simvastatin 20 mg/tablet reduced serum total choles-terol(TC)33%, reduced low density lipoprotein (LDL)46%, reduced triglycerides (TG) 26%, rose highdensity lipoprotein(HDL)21%, and reduced TC/HDL-C 44%. Comparasion of 2 groups, area of reducedTG and LDL-C and area of rose HDL-C had remarkables differences(P0.01), area of reduced TC hadno remarkable differences(P05). It had no effect on blood glucoes. Conclusion: Simvastatin 20 mg/tablet is one of the safe and effective drugs to treat hyperlipidemia of the type 2 diabetes.

About this research paper

What this paper is about

Objective:To evaluate the curative efficacy and safety of treating the type 2 diabetic hy-perlipidemia with simvastatin 20 mg/tablet. Methods: Sixty patients of type 2 diabetes hyperlipidemiawere divided randomly into 2 groups. Thirty patients separately were given simvastatin orally 5 mg/tablet(LDL) or 20 mg/tablet in evening for 4 wk. Results: Simvastatin 20 mg/tablet reduced serum total choles-terol(TC)33%, reduced low density lipoprotein (LDL)46%, reduced triglycerides (TG) 26%, rose highdensity lipoprotein(HDL)21%, and reduced TC/HDL-C 44%. Comparasion of 2 groups, area of reducedTG and LDL-C and area of rose HDL-C had remarkables differences(P0.01), area of reduced TC hadno remarkable differences(P05). It had no effect on blood glucoes. Conclusion: Simvastatin 20 mg/tablet is one of the safe and effective drugs to treat hyperlipidemia of the type 2 diabetes.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To evaluate the curative efficacy and safety of treating the type 2 diabetic hy-perlipidemia with simvastatin 20 mg/tablet. Methods: Sixty patients of type 2 diabetes hyperlipidemiawere divided randomly into 2 groups. Thirty patients separately were given simvastatin orally 5 mg/tablet(LDL) or 20 mg/tablet in evening for 4 wk. Results: Simvastatin 20 mg/tablet reduced serum total choles-terol(TC)33%, reduced low density lipoprotein (LDL)46%, reduced triglycerides (TG) 26%, rose highdensity lipoprotein(HDL)21%, and reduced TC/HDL-C 44%. Comparasion of 2 groups, area of reducedTG and LDL-C and area of rose HDL-C had remarkables differences(P0.01), area of reduced TC hadno remarkable differences(P05). It had no effect on blood glucoes. Conclusion: Simvastatin 20 mg/tablet is one of the safe and effective drugs to treat hyperlipidemia of the type 2 diabetes.

Key concepts: Simvastatin, Medicine, Hyperlipidemia, Type 2 diabetes, Internal medicine, Diabetes mellitus, Evening, Endocrinology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical efficacy of simvastatin in treating hyperlipidemia in the type 2 diabetes — Research Paper | ScholarLens